@article{fdi:010006221,
  title = {{C}hild mortality following standard, medium or high titre measles immunization in {W}est {A}frica},
  author = {{K}nudsen, {K}.{M}. and {A}aby, {P}eter and {W}hittle, {H}.. {R}owe, {M}. and {S}amb, {B}adara and {S}imondon, {F}ran{\c{c}}ois and {S}terne, {J}. and {F}ine, {P}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he {W}orld {H}ealth {O}rganization ({WHO}) recommended the use of high titre measles vaccine in 1989. {S}ubsequent long term follow-up of several trials yielded results suggesting higher mortality among children inoculated with medium and high titre vaccines compared to standard titre vaccines, although none of the individual trials found significant differences in mortality. {L}ong term survival after standard, medium and high titre measles vaccines has been investigated in a combined analysis of all {W}est {A}frican trials with mortality date. {I}n trials from {G}uinea-{B}issau, {T}he {G}ambia and {S}enegal, children received medium or high titre vaccines from 4 months of age and were compared to control groups recruited at the same time later receiving standard titre vaccine from 9 months of age. {A}ll children were followed up to at least 3 years old. {C}ombining trials of high titre vaccines showed higher mortality among the high titre group compared to the standard group : mortality ratio ({MR}) = 1.33 (95 % {CI} : 1.02-1.73). {M}ortality among recipients of medium titre vaccines was not different from that in the standard vaccine group, {MR} = 1.11 (95 % {CI} : 0.54-2,27). {I}n a combined analysis by sex, the adjusted mortality ratios comparing high titre vaccine with standard vaccine were 1.86 ( 95 % {CI} : 1.28-2.70) for females and 0.91 ( 95 % {CI} : 0.61-1.35) for males. {T}he trials were not designed to study long term mortality. {A}djustments for several possible sources of bias did not alter the results. {T}he combined analysis showed a decreased survival related to hith titre measles vaccine compared with standard titre vaccines, though solely among females. {A}s a result of these studies from {W}est {A}frica and a study from {H}aiti, {WHO} has recommended that high titre measles vaccine no longer be used. ({R}{\'e}sum{\'e} d'auteur)},
  keywords = {{ROUGEOLE} ; {VACCINATION} ; {EFFICACITE} ; {MORTALITE} {INFANTILE} ; {SEX} {RATIO} ; {ENFANT} ; {NOURRISSON} ; {VACCIN} {A} {HAUT} {TITRE} ; {AFRIQUE} {DE} {L}'{OUEST}},
  booktitle = {},
  journal = {{I}nternational {J}ournal of {E}pidemiology},
  volume = {25},
  numero = {3},
  pages = {665--673},
  ISSN = {0300-5771},
  year = {1996},
  DOI = {10.1093/ije/25.3.665},
  URL = {https://www.documentation.ird.fr/hor/fdi:010006221},
}